Lipocine Inc (LPCN) is a Healthcare · Biotechnology company listed on NASDAQ. Price $2.22 (+0.00%), Market cap $0.02B, 52-week low–high $1.94 ~ $11.26.
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. It also develops LPCN 1154 (BRLIZIO), an oral neuro-steroid in a Phase 3 pivotal trial for postpartum depression; LPCN 1148, a prodrug of testosterone and testosterone laurate that has completed a Phase 2 trial for the management of decompensated cirrhosis; LPCN 1107, an oral hydroxy progesterone caproate product that has completed a Phase 2 trial for the prevention of recurrent preterm birth; LPCN 1144, an oral prodr
Financial statements, price targets, institutional (13F) holdings and related news for Lipocine Inc are updated in real time on BlackAll Trade.
Lipocine Inc trades at $2.22 (+0.00%). Real-time quotes and charts are available on BlackAll Trade.
Lipocine Inc has a market cap of about $0.02B.
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an or